Aryl−Oxazoline Chelates of First-Row Transition Metals: Structures of {κ-<i>C</i>,<i>N</i>-(<i>o</i>-C<sub>6</sub>H<sub>4</sub>)CMe<sub>2</sub>(COCH<sub>2</sub>CMe<sub>2</sub>N)}FeCl(py) and [(κ-<i>C</i>,<i>N</i>-(<i>o</i>-C<sub>6</sub>H<sub>4</sub>)CMe<sub>2</sub>(COCH<sub>2</sub>CMe<sub>2</sub>N)}Cr(μ-Cl)]<sub>2</sub>
作者:Emily C. Volpe、David R. Manke、Erika R. Bartholomew、Peter T. Wolczanski、Emil B. Lobkovsky
DOI:10.1021/om100420z
日期:2010.12.27
(Me2N)3Ti(η-N-(4,4-dimethyl-(2-CHPh)oxazoline)) (2) and bis-N,N′-(4,4-dimethyl-(2-pyridylmethylyl)oxazoline)Fe (3). Oxidative addition of 4,4-dimethyl-2-(2-bromophenylpropan-2-yl)oxazoline (BrPhCMe2Ox) to Ni(COD)2 provided [κ-C,N-(o-C6H4)CMe2(COCH2CMe2N)}Ni]2(μ-Br)2 (42). With 4,4-dimethyl-2-(2-lithiophenylpropan-2-yl)oxazoline (LiPhCMe2Ox), salt (FeBr2) metathesis proved uncompetitive with oxazoline ring-opening
芳基-恶唑啉合成子已被研究用于制备强场第一行过渡金属螯合物。使用4,4-二甲基-2-苯基恶唑啉(HPhOx)时,除Zn(κ - C,N -4,4-Me 2 -2-(o -C 6 H 4)恶唑啉之外,没有CH键活化作用可提供络合作用。)2(Zn(PhOx)2),注意到芳基偶联反应与4,4-二甲基-2-(2-lithiophenyl)恶唑啉(LiPhOx)和MX 2 ; [κ- N,N- 4,4-Me 2-(2- o -C 6 H 4)-2-恶唑啉} 2 ] CoCl 2(1 -Co)的结构表征。以(Me 2 N)3 Ti(η - N-(4,4-二甲基-(2-CHPh)恶唑啉)为例,4,4-二甲基-2-苄基恶唑啉(PhCH 2 Ox)的金属化易于去质子化。)(2)和双-N,N ′-(4,4-二甲基-(2-吡啶基甲基甲酰基)恶唑啉)Fe(3)。将氧化的4,4-二甲基-2-(2-溴苯基丙烷-2-基)恶唑啉(BrPhCMe